T he postmenopausal phase is associated with an accelerated rate of rise in the prevalence of endothelial dysfunction and hypertension and the incidence of cardiovascular disease is also higher in postmenopausal than in premenopausal women of similar age. [1] [2] [3] [4] Although much is known about the beneficial effects of estrogen on vascular function, the mechanisms by which changes in the hormonal environment in postmenopausal women lead to unfavorable alterations in vascular function are still poorly understood. In the cardiovascular system, cyclooxygenase-derived prostanoids are important regulators of vascular function, smooth muscle cell proliferation, leukocyte-endothelial cell interactions, and platelet aggregation. 5, 6 Estrogen has been shown to have an inhibitory effect on the action and production of the cyclooxygenase-derived vasoconstrictor compounds prostaglandin H 2 and thromboxane A 2 . 7, 8 In addition, estrogen also upregulates the production of the cyclooxygenase-derived vasodilator prostacyclin and deletion of the prostacyclin receptor (IP) removes the atheroprotective effect of estrogen in ovariectomized female mice.
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October 2016 a prominent endothelium-derived vasoconstrictor that contributes to endothelial dysfunction. 13 Substantial evidence supports the value of physical activity in the prevention and treatment of cardiovascular disease.
14 Intriguingly, beneficial adaptations to exercise training on endothelial function seem to be impaired in late postmenopausal women (≈10 years from last menstrual cycle) compared with age-matched men. 15, 16 Estradiol supplementation has been found to counteract this detrimental consequence of the menopausal transition, 16 suggesting that estrogen status plays an import regulatory role in the improvement of endothelial function with exercise training. Along these lines, the beneficial effects of estrogen supplementation in terms of atherosclerosis and cardiovascular disease are most pronounced during the peri-and early postmenopausal years when estrogen receptors (ERs) or other compensatory mechanisms may function. 17, 18 To what extent the beneficial effects of exercise training on vascular function are preserved in the early postmenopausal phase is currently not known.
Accordingly, we tested the hypothesis that postmenopausal women would display a loss of prostacyclin-induced vasodilation and that this reduced vascular reactivity was associated with an altered balance between vasoconstrictor and vasodilator prostanoids. To this end, we infused the prostacyclin analog epoprostenol in addition to the prostanoiddependent vasodilator acetylcholine 19 without and with simultaneous inhibition of prostanoid formation to assess vascular prostanoid function and the role of prostanoid constrictors. Moreover, we tested the hypothesis that exercise training initiated in the early postmenopausal phase would improve vascular function and that this adaptation with exercise training was not different from that of premenopausal women. To differentiate between the effects of aging and menopausal status, we investigated pre-and recent postmenopausal women with a minimal difference in age (≈4-year difference) because significant age-related vascular changes are likely to be limited within this short time frame.
Methods

Subjects
Twenty premenopausal women with a mean age of 50 years (range, 46-55 years) and 16 postmenopausal women with a mean age of 54 years (range, 46-57 years) participated in the study (Table 1) . All subjects were informed of any risks and discomforts associated with the experiments before giving their written, informed consent to participate in the study. The premenopausal women were all experiencing regular menstrual cycles and were not taking oral contraceptives, whereas the postmenopausal women had not experienced a menstrual cycle during the previous 12 months but were <5 years past their final menstrual period (mean±SE, 3.1±0.5 years). Menopausal status was verified by measurements of hypothalamic and reproductive hormones (Table 1) , and none of the postmenopausal women were in hormone-replacement therapy. All subjects were habitually inactive (<2 hours of moderate intensity exercise per week), had normal resting ECG, were nonsmokers, and none of the subjects in either group had been diagnosed with hypertension, cardiovascular disease, renal dysfunction, insulin resistance, diabetes mellitus, or hypercholesterolemia. To ensure that all subjects were normotensive, blood pressure was measured 7 consecutive times by an automatic upper-arm blood pressure monitor (M7; OMRON, Vernon Hills, IL) after at least 15 minutes of rest in the supine position (premenopausal, 112±3/72±2 mm Hg; postmenopausal, 114±4/73±2 mm Hg). It may be noted here that the reported blood pressure values in Table 1 represent intra-arterial readings obtained  from the femoral artery (see below) . As a result of the higher hydrostatic and transmural pressure in the legs compared with the arms, the vascular wall thickness and stiffness are also highest in the lower extremities, thus explaining the higher systolic pressure and lower diastolic pressure observed in the femoral artery compared with the brachial artery. Before and after the training intervention, maximal oxygen uptake (VO 2max ) was determined (Oxycon Pro, Intramedic, Denmark) by the use of an incremental exercise test on a cycling ergometer. Briefly, after a 10-minute warm-up, the test was initiated at 50 W and the workload was increased by 25 W until volitional fatigue. The data presented are part of a larger study on the effects of exercise training on women in the menopausal transition funded via the University of Copenhagen Excellence Program for Interdisciplinary Research. The study was approved by the Ethics Committee of Copenhagen and Frederiksberg communities Region H (H-1-2012-150) and conducted in accordance with the guidelines of the Declaration of Helsinki. The study was registered at ClinicalTrials.gov (NCT02135575).
Experimental Design
The experimental day was performed before and after a 12-week training period where the subjects participated in supervised exercise training. Experimental testing in the premenopausal women was performed in the midfollicular phase of their ovarian cycle.
Exercise Training
Subjects performed exercise on a cycling ergometer for 1 hour 3× per week, of which 2 of these were supervised by instructors from the research group and 1 was supervised by instructors from the local gym. A heart rate monitor was worn during all training sessions (TEAM2 Wearlink+, Polar, Kempele, Finland). Exercise intensity during the training sessions are presented in Table 2 .
Experimental Day
Subjects refrained from caffeine, alcohol, and exercise for 24 hours before arriving at the laboratory after eating breakfast. After local anesthesia (lidocaine, 20 mg mL −1 ; Astra Zeneca, Denmark), catheters (20 Ga; Arrow Int., Reading, PA) were placed in the femoral artery and vein of the experimental leg and in the femoral artery of the nonexperimental leg. After 20 minutes of rest, subjects were positioned in a supine position where they received femoral arterial infusion of (1) ; Roche, Hvidovre, Denmark). Each dose of epoprostenol and acetylcholine was infused for 2.5 minutes, and measurements (blood flow, blood pressures, and arterial and venous blood samples [≈2 mL]) were obtained after 2.0 minutes. Ketorolac was infused for 5 minutes (baseline measurements were obtained after 4.5 minutes) before infusion of acetylcholine and kept constant until termination of acetylcholine infusion. Each infusion protocol was separated by at least 30 minutes, and acetylcholine plus ketorolac was performed last because of the long-term effect of ketorolac (plasma half-life of 4-6 hours). Experimental leg volume was calculated based on measurements of circumferences and partial lengths of the leg.
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Measurements and Analyses
Whole-blood samples obtained were analyzed at the clinical biochemical unit at the Copenhagen main hospital (Rigshospitalet) using an automatic analyzer using turbidimetric immunoassay (Modular P-Module) for C-reactive protein, estradiol, progesterone, and testosterone (Modular E-Module) by using competitive electrochemiluminescence immunoassay and follicle-stimulating hormone and by guest on November 13, 2017 http://hyper.ahajournals.org/ Downloaded from luteinizing hormone by using sandwich electrochemiluminescence immunoassay (Modular E-Module). Blood samples for collection of plasma were drawn into tubes containing EDTA as anticoagulant. Blood was then immediately centrifuged for 5 minutes at 4000g, and plasma was stored at −80°C for later analysis. Plasma concentrations of the stable metabolite of prostacyclin, 6-keto prostaglandin F 1a , (PGF 1a ) was measured (E max precision microplate reader; Molecular Devices) using an immunoassay kit (EIA; Cayman Chemical Co., Ann Harbor, MI).
Femoral arterial blood flow was measured with ultrasound Doppler (Vivid E9; GE Healthcare, Denmark) equipped with a linear probe operating at an imaging frequency of 8.0 MHz and Doppler frequency of 3.1 MHz as previously described. 21 Intra-arterial and intravenous pressures were monitored with transducers (Pressure Monitoring Set; Edwards Lifesciences, CA) positioned at the level of the heart. Hemoglobin was measured using an ABL800 FLEX analyzer (Radiometer, Denmark). Leg vascular conductance (LVC) was calculated as femoral arterial blood flow/(mean arterial pressure [MAP]−mean femoral venous pressure). The overall vasodilator response to epoprostenol was calculated as area under the curve. Absolute change of LVC with ketorolac infusion during arterial acetylcholine infusion was calculated as the difference between the change of LVC with acetylcholine infusion and the change of LVC with acetylcholine and ketorolac infusion. Exchange of 6-keto PGF 1a across the leg was calculated as venous-arterial difference multiplied by plasma flow.
Statistical Analysis
The number of subjects was selected on the basis of detecting differences in the vascular response to epoprostenol and acetylcholine between the 2 groups before training. Moreover, the study also aimed at detecting a putative training effect within each group and differences in the magnitude of training-induced changes in the vasodilator response between the 2 groups. Differences in baseline characteristics were assessed with Student t test for unpaired and paired data when comparing between groups and within groups. A 2-way ANOVA was performed to test significance between pre-and postmenopausal women and a 2-way repeatedmeasures ANOVA was performed to detect changes within each group. Whenever a significant interaction was detected, pairwise differences were identified using the Tukey honestly significant 
Results
Baseline Characteristics
There was no difference in VO 2max between pre-and postmenopausal women before the training period (Table 1) . Exercise training increased (P<0.05) VO 2max by 9.9±2.4% and 5.4±2.1% in the pre-and postmenopausal women, respectively. Before training, systolic blood pressure and MAP were higher (P<0.05) in the postmenopausal women than in premenopausal women. Exercise training lowered (P<0.05) systolic and diastolic blood pressures and MAP in the postmenopausal women, but not in the premenopausal women, so that no differences in these variables were detected between the groups after training.
Vascular Response to Epoprostenol Infusion
Before the training period, the increase in LVC with epoprostenol infusion was lower (P<0.05) in the post-than in premenopausal women (−41%, −22%, and −26%; 25, 50, and 100 ng minute −1 L −1; Figure 1A ). Exercise training increased (P<0.05) the vasodilator response to epoprostenol infusion in the postmenopausal group (249±64%, 154±22%, and 147±15%), whereas there was no significant increase in the vasodilator response to epoprostenol in the premenopausal women ( Figure 1B and 1C) . The change in the vascular response to epoprostenol infusion with exercise training was, however, not different between the 2 groups ( Figure 1D ). In the postmenopausal group, an inverse relationship was detected between the training-induced change in MAP and vasodilator response to the 2 highest infusion rates of epoprostenol (r ). The difference in estradiol levels (before and after training) correlated with the difference in the overall vasodilator response (area under the curve) to epoprostenol (before and after training) in the premenopausal women (r 2 =0.411; P<0.05; Figure 1E ). Changes in femoral arterial blood flow and MAP are presented in Table S1 in the online-only Data Supplement.
Vascular Response to Acetylcholine Infusion
Before the training period, the vasodilator response to acetylcholine infusion was lower (P<0.05) in the post-than in premenopausal women (Figure 2A ). Exercise training increased (P<0.05) the change in LVC with acetylcholine infusion in the postmenopausal group, whereas no change was detected in the premenopausal group ( Figure 2B and 2C) . The change in the vasodilator response to acetylcholine infusion with exercise training was not different between the 2 groups ( Figure 2D ). In the postmenopausal group, an inverse relationship was detected between the training-induced change in MAP and vasodilator response to the highest infusion rate of acetylcholine (r 2 =−0.363; P<0.05; 100 μg minute
No association between the difference in estradiol levels and the difference in the overall vasodilator response (area under the curve) to acetylcholine (before and after training) was detected in the premenopausal women (r 2 =0.072; P>0.05). Changes in femoral arterial blood flow and MAP are presented in Table S2 .
Before training, infusion of acetylcholine increased (P<0.05) arterial and venous plasma (6-keto PGF 1a ) with venous plasma (6-keto PGF 1a ) being higher (P<0.05) compared with arterial plasma in both groups (Table S3 ). The increase in the venous-arterial difference of plasma (6-keto PGF 1a ) combined with the increase in plasma flow lead to an increase (P<0.05) in leg 6-keto PGF 1a release during infusion of acetylcholine that was similar in the 2 groups (Figure 3) . Exercise training did not affect leg 6-keto PGF 1a release at baseline or during acetylcholine infusion in either group (Figure 3) . Table S4 .
Vascular Response to Ketorolac Infusion
Discussion
The main findings of the study were that the early postmenopausal phase was associated with a marked reduction in vascular function as evidenced by a reduced vasodilator response to the prostacyclin analog epoprostenol and acetylcholine. Inhibition of cyclooxygenase in combination with acetylcholine infusion to elucidate the role of vasoconstrictor prostanoids demonstrated that the overall balance between vasodilator and vasoconstrictor prostanoids was not altered as a consequence of the menopausal transition. Moreover, the release of 6-keto PGF 1a from the leg in response to acetylcholine infusion was similar in the 2 groups of women. Finally, exercise training increased the vasodilator response to epoprostenol and acetylcholine infusion in the postmenopausal women, and this effect of training on vascular responsiveness was similar to that observed for the premenopausal women.
In women, an acceleration of age-associated declines in vascular function is evident after the menopausal transition. 3 The current finding of a reduced vasodilator response to epoprostenol in the recent postmenopausal women extends this finding and suggests that prostacyclin signaling is severely affected by the changes in the hormonal environment associated with the early postmenopausal phase. This is in agreement with findings in older men, in whom a loss of prostacyclin-induced vasodilation was observed in the forearm. 22 by guest on November 13, 2017 http://hyper.ahajournals.org/
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The mechanism(s) underlying the reduced vascular response to epoprostenol remain speculative, but prostacyclin has been shown to act on thromboxane prostanoid receptors on smooth muscle cells to induce vasoconstriction and this effect of prostacyclin may be modulated by the functionally opposing thromboxane prostanoid and IP receptors. 13 In addition, the reduced prostacyclin-induced vasodilation in aging has been suggested to be attributable to a reduction in the contribution Figure 1 . Vasodilator response to epoprostenol infusion. A, Absolute change in leg vascular conductance (LVC) from baseline after arterial infusion of epoprostenol in pre-(n=20) and postmenopausal (n=16) women before initiation of exercise training. B and C, Absolute change in LVC from baseline after arterial infusion of epoprostenol before and after training in pre-(n=14) and postmenopausal (n=16) women. D, Absolute difference in the change in LVC with arterial epoprostenol infusion after exercise training in pre-(n=14) and postmenopausal (n=16) women. E, Association between the difference in estradiol levels (before and after training) and the overall vasodilator response (area under the curve [AUC]) to epoprostenol (before and after training) in premenopausal women (n=14). *P<0.05: significant difference between groups; #P<0.05: significantly different from before training.
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of endothelial-derived NO. 22 The current observation that the release of 6-keto PGF 1a in response to acetylcholine infusion was similar in the 2 groups suggests that the reduced sensitivity to prostacyclin was not compensated for by an improved capacity of the vasculature to produce prostacyclin in the postmenopausal women.
The present finding of a reduced vascular sensitivity to prostacyclin in the postmenopausal women suggests that estrogen may play an important regulatory role in prostacyclin-induced vasodilation. Consequently, it would be expected that the level of circulating estrogen would be predictive of the vascular sensitivity to prostacyclin, which is in congruence with the observed association between the overall vasodilator response to epoprostenol and estradiol levels in the premenopausal women. Given the putative role of NO in the vasodilator effect of prostacyclin, 22 1 mechanism underlying the higher sensitivity to prostacyclin in the premenopausal women could be related to a stimulation of ERα as the downstream signaling of this receptor leads to endothelial NO synthase (eNOS) activation. 23 This deserves further investigation. The reduced vascular response to the endothelium-dependent vasodilator acetylcholine in the recent postmenopausal women is in agreement with observations of the forearm vasculature in which endothelial function, assessed by flowmediated dilation, was found to be progressively reduced across the stages of the menopause transition. 24 This reduced sensitivity to acetylcholine could be the result of a reduced contribution from endothelium-derived NO as the vasodilator response to acetylcholine is highly dependent on NO formation. 19 An additional mechanism contributing to the reduced vascular response to acetylcholine in the postmenopausal women could be a shift in the overall production and action of vasoconstrictor prostanoids. This shift is supported by the observation that 17β-estradiol supplementation effectively reduces prostanoid-mediated vasoconstriction in both animals 8 and postmenopausal women. 25 Moreover, aging is also associated with an exacerbated production of endothelium-derived vasoconstrictor prostanoids. 10, 13 However, nonspecific inhibition of cyclooxygenase with ketorolac reduced vascular conductance at baseline and during acetylcholine infusion to a similar extent in the pre-and postmenopausal women. This similar effect of ketorolac suggests that the balance between vasodilator and vasoconstrictor prostanoids in the regulation of vascular function is not altered in the early postmenopausal phase despite an altered responsiveness to prostacyclin. In this context, the similar release of 6-keto PGF 1a in response to acetylcholine infusion in the 2 groups of women indicates that an improved capacity to produce prostacyclin is not 1 mechanism underlying this preserved overall function of the prostanoid system in the postmenopausal women.
In humans, several lines of evidence suggest that estrogen reduces sympathetic activity. 26 In the present study, blood flow at rest was found to be lower in the postmenopausal women than in the premenopausal women, which is in agreement with a higher basal sympathetic tone in the postmenopausal group. The central sympathoinhibitory effect of estrogen is likely to be amplified by enhanced β 2 -mediated vasodilation as β 2 -adrenergic blockade augments the vasoconstrictor response to norepinephrine in premenopausal women to a level similar to that of postmenopausal women. 27 Taken collectively, these effects of estrogen on sympathetic activity and vasoconstrictor responses may explain some of the observed differences in the vascular response to epoprostenol and acetylcholine in the current study. Specifically, the finding that the differences in the vasodilator responses were manifested around the lowest doses indicates that a higher basal sympathetic tone in the postmenopausal group was 1 important mechanism underlying the lower vasodilator response. Furthermore, the reductions in blood pressure observed during infusion of the vasodilator compounds, which are expected to increase sympathetic activity may have caused less vasoconstriction in the premenopausal women as a result of β 2 -mediated vasodilation that would have offset α-adrenergic vasoconstriction. Inhibition of α-receptors in future studies will help to elucidate the extent to which α-mediated vasoconstriction counteracts the vasodilator response to various vasodilator stimuli in postmenopausal women.
Regular physical activity is associated with improvements in cardiovascular structure and function, and exercise training is advocated for the prevention and treatment of cardiovascular disease.
14 Interestingly, the beneficial effects of exercise training on vascular function have been suggested to be diminished or even absent in postmenopausal women. In a study on middle-aged and older adults, regular physical activity was found to improve flow-mediated dilation in previously sedentary men but not in late postmenopausal women. 15 In another study, flow-mediated dilation was increased in late postmenopausal women who had undergone 12 weeks of estradiol therapy before initiation of exercise training and continued treatment throughout the intervention period, whereas flow-mediated dilation did not change in the women receiving placebo. 28 Collectively, these findings indicate that estrogen status plays a key permissive role in the adaptive response of the vasculature to exercise training in women. However, the studies in which beneficial vascular effects of exercise training were not observed in late postmenopausal women were characterized by low to moderate exercise intensities, 15, 28 whereas high-intensity aerobic training such as that introduced in the current study has been shown to be associated with improvements in vascular function. 29 As this latter training modality has superior cardiovascular effects compared with moderate intensity exercise in patients with heart failure, 30 it may be that exercise intensity is an essential factor for reversing vascular dysfunction in postmenopausal women. Hence, future studies should aim at determining the role of exercise intensity for the vascular adaptations with exercise training in both early and late postmenopausal women.
In addition to the potential role of exercise intensity, it is also noteworthy that the beneficial vascular effects of estrogen supplementation are most pronounced during the peri-and early postmenopausal years when ERs or other compensatory mechanisms may function. 17, 18 Hence, the vasculature could also be more responsive to exercise training during this period. In support of this suggestion, the vascular response to infusion of epoprostenol and acetylcholine increased with exercise training in the postmenopausal women and this effect of training was not different from that of the premenopausal women. The present effect on vascular responsiveness to epoprostenol and acetylcholine is also in agreement with findings in a previous study on a similar group of pre-and postmenopausal women in whom biomarkers of vascular function were improved to a similar extent in the 2 groups after 12 weeks of exercise training. 29 Because estrogen is also an important regulator of vascular function, 23 it may be that exercise and estrogen share common signaling pathways. Accordingly, exercise leads to increases in vascular shear stress, which has been shown to activate phosphatidylinositol 3-kinase, which in turn activates protein kinase B (Akt) leading to activation of eNOS. 31 Similarly, estrogen increases ERα-associated phosphatidylinositol 3-kinase activity, leading to Akt and eNOS activation. 23 Therefore, 1 mechanism underlying the present effect of exercise training on the vascular reactivity to the vasoactive compounds may be a preserved ability to stimulate the phosphatidylinositol 3-kinase-Akt-eNOS pathway during exercise in the postmenopausal women because the vasoactive effect of acetylcholine 19 (and possibly epoprostenol 22 ) is dependent on NO formation. In this scenario, exercise-induced stimulation of the phosphatidylinositol 3-kinase-Akt-eNOS pathway would serve to compensate for the lack of ERα-mediated stimulation of this pathway.
Premenopausal women have lower blood pressure than age-matched men, and women have a higher incidence of hypertension than men as they age. 32 These findings suggest that sex hormones play a prominent role in hypertension. In accordance, both systolic and mean arterial blood pressures were found to be higher in the postmenopausal women before the training intervention. One mechanism underlying this effect of the menopausal transition may have been the reduced vascular function because vascular dysfunction has been shown to precede and predict the future development of hypertension in postmenopausal women. 33 This suggestion is in line with the current finding of an inverse relationship between the training-induced change in vasodilator response to epoprostenol and acetylcholine and MAP. Within this context, it is noteworthy that exercise training reduced blood pressure in the postmenopausal women to a level similar to that observed in the premenopausal women. As the effect of cyclooxygenase inhibition on blood pressure at baseline (data not shown) and the effect of cyclooxygenase inhibition on vascular conductance during acetylcholine infusion did not change with training, an essential overall role for the prostanoid system for the improved vascular response to acetylcholine and reduced blood pressure in the postmenopausal seems unlikely.
The current finding that ketorolac reduced vascular conductance at rest in both groups of women demonstrates that the prostanoid system is involved in the basal regulation of vascular tone in women where it plays a vasodilator role irrespective of menopausal status. Interestingly, exercise training abolished this vasoconstrictor effect of ketorolac at baseline in both groups. This finding suggests that training removed the contribution from the prostanoid system to basal vascular tone. This altered role of the prostanoid system may be 1 mechanism underlying the lower leg blood flow after exercise training. 
Perspectives
Given the essential role of prostacyclin for regulation of vascular function, smooth muscle cell proliferation, leukocyte-endothelial cell interactions, and platelet aggregation, mechanisms underlying the lower vascular sensitivity to prostacyclin in recent postmenopausal women should be investigated. Such studies should aim at providing insight into the contribution from endothelial-derived NO and altered signaling via thromboxane prostanoid and IP receptors. Moreover, the finding that exercise training effectively improves vascular function and blood pressure in recent postmenopausal is a clinically relevant finding because this effect of physical activity seems to be impaired in late postmenopausal women. Hence, questions about the role of exercise intensity and the putative signaling cascades that could explain a preserved vascular responsiveness to exercise training in postmenopausal women needs to be addressed because this may lead to novel therapeutic strategies to treat vascular dysfunction in these women. Mean arterial blood pressure, mmHg Baseline 90 ± 2 89 ± 3 96 ± 3* 90 ± 3 † Change in mean arterial blood pressure, mmHg
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ONLINE SUPPLEMENT
ACh (100 µg/min/L) -8 ± 1 -8 ± 1 -9 ± 1 -9 ± 1
Values are means ±SE. *P<0.05:Significantly different from pre-menopausal. †P<0.05:Significant change with training.
